Page 2 - Entrepreneurs Behind The News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Entrepreneurs behind the. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Entrepreneurs Behind The Today - Breaking & Trending Today

Neurophth Closes RMB 400 Million Series B Financing

Neurophth Closes RMB 400 Million Series B Financing
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.

Yangtze River , China General , Guo Fang , United States , Yaguang Wei , Van Stavern , Trency Gu , Calvin Luk , Mcclellandc Leber , China Unionpay Merchant Services , Management Committee Of Suzhou Industrial Park , Shanghai International Group , Swan Home Services , Suzhou Oriza Holdings Corporation , Yangtze River Delta Synergy Industry Investment Fund , Neurophth Therapeutics Inc , Oriza Holdings , Suzhou Oriza Holdings , Chief Executive Officer , Guofang Capital , Lane Zhao , Founding Partner , Innovision Capital , Capital China , Managing Director , Sequoia Capital ,

VISEN Pharmaceuticals Closes $150 Million Series B Financing to Accelerate the Development and Commercialization of its Innovative Endocrinology Therapies in Greater China

VISEN Pharmaceuticals Closes $150 Million Series B Financing to Accelerate the Development and Commercialization of its Innovative Endocrinology Therapies in Greater China
News provided by
Share this article
SHANGHAI, Jan. 9, 2021 /PRNewswire/
VISEN Pharmaceuticals, a biotech company focused on developing and commercializing innovative endocrine drugs that address significant unmet needs for patients in Greater China, announced today the closing of a $150 million Series B financing.
The round was led by Sequoia China with participation from OrbiMed, Sherpa Healthcare Partners, Cormorant, HBM Healthcare Investments, Pivotal bioVenture Partners China, Logos Capital, and CDG Capital, as well as all of the existing investors, including Ascendis Pharma A/S, Vivo Capital and Sofinnova Investments. Proceeds of the Series B financing will be used to accelerate the clinical development of the potential best-in-class portfolio drug candidates and to build a strong fou ....

Hong Kong , Palo Alto , United States , Redwood City , San Francisco , New Jersey , Baden Wuberg , Shan Fu , Cyber Cao , Jan Mikkelsen , Ascendis Pharma , Bihua Chen , Dandan Dong , Microport Cardioflow , National Medical Product Administration , Nan Fung Life Sciences , Swiss Exchange , China Reform Conson Soochow Overseas Fund , Greater China , Sequoia Capital China , Sherpa Healthcare Partners , Venture Partners China , Logos Capital , Vivo Capital , Managing Partner , Managing Director ,